


Helen Giza CEO & Chair of the Management Board February 20, 2024




Achievements "We delivered against our plan"

Care Delivery and Care Enablement: we successfully implemented our new global operating model



2023 at a glance: we delivered on our commitments in a year of fundamental transformation




Proof points of execution in 2023

- Solid revenue growth at constant currency at top end of outlook
- Organic growth mainly driven by favorable business development
- Operating income (guidance base) exceeding top end of raised outlook thanks to business growth, realized FME25 savings ahead of plan and the Tricare settlement
- Successful execution on turnaround plan driving labor productivity improvements in Care Delivery and positive pricing in Care Enablement
- Simplified governance structure through legal form change
- Several key divestments announced as part of ongoing portfolio optimization
- Cash flow strongly improved; net leverage ratio reduced to 3.2x
- Continued progress towards Sustainability goals



Portfolio optimization: we made remarkable progress and announced key divestments of non-core and dilutive assets

Annual Press Conference 2024



Closed divestments

- CD and CE operations in Argentina
- CD operations in Hungary
- National Cardiovascular Partners (NCP), U.S.
- Announced divestments
 - CD operations in Sub-Saharan Africa
 - Cura day hospital group, Australia
 - CD operations in Türkiye


Note: Axes are non-linear, indicative only; divestment in Hungary executed as part of FME25 program; divestment of Cura is subject to regulatory approval

Group performance in 2023: our revenue growth driven by favorable business development

Annual Press Conference 2024

Revenue | guidance base¹


in € million



Organic growth

- in Care Delivery driven by value-based care business growth and higher price
- in Care Enablement driven by higher volume and price

Operating income | guidance base¹



- Earnings growth driven by improved business development, realized FME25 savings, the Tricare settlement and improved labor productivity in CD
- Earnings diluted by cost inflation and Fx transaction losses in CE

1 FY 2023 €1,778 million Operating Income at cc (outlook base); reconciliation table for special items (outlook base) | cc = at constant currency

FRESENIUS MEDICAL CARE



Our Financials "Laying the foundation for sustainable profitable growth"

Clear prioritization of strict financial policy



1 Pending shareholders' approval on upcoming AGM



Annual Press

Conference 2024

Financial performance: we upgraded and exceeded our financial outlook

Annual Press Conference 2024



Revenue and operating income, as referred to in the outlook, are both on a constant currency basis and excluding special items. Special items will be provided as separate KPI ("Revenue excluding special items", "Operating income excluding special items") to capture effects that are unusual in nature and have not been foreseeable or not foreseeable in size or impact at the time of providing the outlook. These items are excluded to ensure comparability of the figures presented with the Company's financial targets which have been defined excluding special items.



FME25: accelerated savings on track to deliver EUR 650m by 2025

Annual Press Conference 2024

Sustainable annual savings

in € million



- Transformation program introduced in 2021 and savings target extended to EUR 650m by 2025
- EUR 346m of sustainable savings delivered by year end 2023, while related one-time costs accumulated to EUR 420m
- Targeted savings contributions by year end 2025:




Note: Indicative illustration only



Looking ahead "Building momentum on our mid-term target"

We stay the course on our strategic priorities

Annual Press Conference 2024





Continued execution on accelerated and extended FME25 transformation program.



Continue to follow our disciplined financial policy and ROIC focus.



Further drive portfolio optimization to strengthen focus on core assets and markets.



Focus on growth drivers value-based care and home dialysis.



Advancing and improving innovative dialysis therapies, e.g., by introducing a new standard of care with highvolume hemodiafiltration dialysis therapy in the U.S. by 2025



With the 5008X Hemodialysis System, we are bringing Industry-Leading Dialysis Therapy to Kidney Disease Patients in the U.S.



Note: USRDS = U.S. Renal Data System (2021 USRDS Annual Data Report - 2019 data); NephroCare mortality rates based on internal data; HVHDF = High Volume Hemodiafiltration with convection volume >23L/ treatment ¹Zhang Y et al. J Am Soc Nephrol 34: 2023; Poster TH-PO1133



Annual Press Conference 2024

FY 2024 Outlook		Mid-term Outlook
Revenue (outlook base)	Low- to mid-single digit percent growth FY 2023 basis: EUR 19.0bn	Group operating income margin 10% to 14% by 2025
Operating income (outlook base)	Mid- to high-teens percent growth FY 2023 basis: EUR 1.54bn	

Revenue and operating income, as referred to in the outlook, are both on a constant currency basis, excluding special items, the settlement agreement with the U.S. government in 2023 (Tricare) and major portfolio changes from 2023, namely Argentina and NCP. Special items will be provided as separate KPI ("Revenue excluding special items", "Operating income excluding special items") to capture effects that are unusual in nature and have not been foreseeable or not foreseeable in size or impact at the time of providing the outlook. These items are excluded to ensure comparability of the figures presented with the company's financial targets which have been defined excluding special items.



High quality of care: our patients are at the center of everything we do

Annual Press Conference 2024

Target 2025+: Partner of choice, setting the standard in kidney care with industry-leading returns

Care Delivery

Service provider of choice for patients, physicians and payors across the renal care continuum

Market leading in therapies, digitalization, value-based care, home dialysis & being operationally excellent

Leading renal care company

Culture of innovating for the benefit of our customers while generating industry-leading returns

Mindset of continuous efficiency improvement and operational excellence



Care Enablement

Profitably shape the global dialysis market with leading digital portfolio in renal therapies and pioneering renal care of tomorrow

Most cost-efficient manufacturing in the renal industry with future proof product and services ecosystem

Global Medical Office

High quality outcomes for patients worldwide by advancing the application of clinical science utilizing the world's largest kidney care dataset with longitudinal clinical data





Questions and Answers